Skip to main content
main-content

The American Diabetes Association | 81st Virtual Scientific Sessions

June 25–June 29, 2021
Interview

GRADE: A head-to-head comparison of four metformin add-ons for type 2 diabetes

Deborah Wexler

Deborah Wexler discusses the findings from GRADE, a head-to-head study comparing glimepiride, sitagliptin, insulin glargine, and liraglutide when used in combination with metformin for the treatment of type 2 diabetes.

ADA 2021 interviews

06-27-2021 | ADA 2021 | Conference coverage | Video

SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes

Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes.

06-28-2021 | ADA 2021 | Conference coverage | Video

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide.

06-28-2021 | ADA 2021 | Conference coverage | Video

SUSTAIN-FORTE: Doubling the approved semaglutide dose for people with type 2 diabetes

Juan Pablo Frías discusses whether the findings of SUSTAIN-FORTE will justify an increase in the approved maximum dose of semaglutide for people with type 2 diabetes.

06-29-2021 | ADA 2021 | Conference coverage | Video

What do the GRADE results mean for clinical practice?

The SURPASS trials

Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.

Results and commentary on the GRADE study

06-29-2021 | ADA 2021 | Conference coverage | News

​​​​​​​Trial GRADEs effectiveness of four common second-line type 2 diabetes drugs

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

06-29-2021 | ADA 2021 | Conference coverage | Video

GRADE: A head-to-head comparison of four metformin add-ons for type 2 diabetes

Deborah Wexler discusses the findings from GRADE, a head-to-head study comparing glimepiride, sitagliptin, insulin glargine, and liraglutide when used in combination with metformin for the treatment of type 2 diabetes.

06-29-2021 | ADA 2021 | Conference coverage | Video

What do the GRADE results mean for clinical practice?

Patrick Holmes discusses whether the GRADE study answers the question of which type 2 diabetes medication should be used after metformin, and comments on the generalizability of the findings.

ADA 2021 research news

07-06-2021 | ADA 2021 | Conference coverage | News

Maternal C-peptide may offer clues to fetal condition

07-01-2021 | ADA 2021 | Conference coverage | News

Weight loss with semaglutide improves life quality

View all research news from ADA 2021

06-29-2021 | ADA 2021 | Conference coverage | News

Volagidemab shows promise for type 1 diabetes

06-27-2021 | ADA 2021 | Conference coverage | News

Omnipod 5 system use reduces diabetes distress

06-27-2021 | ADA 2021 | Conference coverage | News

Omnipod 5 closed-loop system success in preschoolers


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits